AAN.com
Quick search in Citations
AnywhereCitation
Advanced Search
Trending Terms:
Research Article
October 20, 2022

Discordance and Concordance Between Cerebrospinal and [18F]FDG-PET Biomarkers in Assessing Atypical and Early-Onset AD Dementia Cases

VIEW EDITORIAL
Kely Mónica Quispialaya, MD, Joseph Therriault, BSc, Antonio Aliaga, MSc, Maria Zimmermann, BSc, Jaime Fernandez-Arias, MSc, Firoza Lussier, MSc, Gassan Massarweh, PhD, … Show All … , Tharick Pascoal, MD, PhD, Jean-Paul Soucy, MD, MSc, Serge Gauthier, MD, Bertrand Jean-Claude, PhD, Brian Gilfix, MD, PhD, Paolo Vitali, MD, PhD https://orcid.org/0000-0001-8953-1542, and Pedro Rosa-Neto, MD, PhD https://orcid.org/0000-0001-9116-1376Authors Info & Affiliations
November 29, 2022 issue
99 (22) e2428-e2436
https://doi.org/10.1212/WNL.0000000000201198
Letters to the Editor
Track CitationsAdd to favorites
Get Access

Abstract

Background and Objectives

To assess the concordance and discordance between the core Alzheimer disease (AD) CSF biomarkers and [18F]fluorodeoxyglucose (FDG)-PET patterns evaluated clinically in memory clinic patients who meet appropriate use criteria for AD biomarker investigations.

Methods

We retrospectively assessed participants with atypical and/or early-onset dementia evaluated at a tertiary care memory clinic. All individuals underwent CSF evaluations for Aβ42, phosphorylated tau (P-tau181) and total tau, and brain [18F]FDG-PET. [18F]FDG-PET data were visually interpreted by 2 nuclear medicine experts as being consistent with AD or non-AD. CSF biomarker results were similarly grouped into AD biomarker positive/negative. Contingency tables and Kappa coefficients were used to establish the level of agreement and disagreement between CSF and [18F]FDG-PET results in all individuals.

Results

One hundred thirty-six individuals had both [18F]FDG-PET and lumbar puncture performed as part of the early-onset and/or atypical dementia assessments. [18F]FDG-PET showed a pattern suggestive of AD in 43% of patients, while CSF biomarkers showed results consistent with AD in 57% of participants. In patients who met criteria for AD biomarker investigations, we found that [18F]FDG-PET was discordant with CSF AD biomarkers in nearly 20% of cases; 12% of individuals with [18F]FDG-PET scans consistent with AD had AD-negative CSF results; and 7% of individuals with [18F]FDG-PET scans not consistent with AD had AD-positive CSF results, potentially suggesting atypical AD variants or less advanced neurodegeneration. [18F]FDG-PET discriminated patients with an AD-positive CSF profile from patients with an AD-negative profile with a sensitivity and specificity higher than 80% (sensitivity: 81%, 95% CI = 71–88%, SP: 81%, 95% CI = 68–89%). Furthermore, [18F]FDG-PET had a positive predictive value of 87% (95% CI = 78–93%) and a negative predictive value of 72% (95% CI = 60–82%).

Discussion

CSF and [18F]FDG-PET disagreed in nearly 20% of the cases studied in this clinical series. While CSF Aβ42 and P-tau181 biomarkers are specific for AD, the topographical information from [18F]FDG-PET may provide complementary information.

Get full access to this article

View all available purchase options and get full access to this article.

Get Access

References

1.
Sweeney MD, Montagne A, Sagare AP, et al. Vascular dysfunction-The disregarded partner of Alzheimer's disease. Alzheimer’s Dement. 2019;15(1):158-167.
Crossref
PubMed
Google Scholar
2.
Foguem C, Manckoundia P. Lewy Body disease: clinical and pathological “overlap syndrome” between synucleinopathies (Parkinson disease) and tauopathies (Alzheimer disease). Curr Neurol Neurosci Rep. 2018;18(5):24.
Crossref
PubMed
Google Scholar
3.
Nelson PT, Head E, Schmitt FA, et al. Alzheimer's disease is not “brain aging”: neuropathological, genetic, and epidemiological human studies. Acta Neuropathol. 2011;121(5):571-587.
Crossref
PubMed
Google Scholar
4.
Serrano-Pozo A, Qian J, Monsell SE, et al. Mild to moderate Alzheimer dementia with insufficient neuropathological changes. Ann Neurol. 2014;75(4):597-601.
Crossref
PubMed
Google Scholar
5.
Alladi S, Xuereb J, Bak T, et al. Focal cortical presentations of Alzheimer's disease. Brain. 2007;130(Pt 10):2636-2645.
Crossref
PubMed
Google Scholar
6.
Boyle PA, Yu L, Leurgans SE, et al. Attributable risk of Alzheimer's dementia attributed to age-related neuropathologies. Ann Neurol. 2019;85(1):114-124.
Crossref
PubMed
Google Scholar
7.
Bunn F, Burn AM, Goodman C, et al. Comorbidity and dementia: a scoping review of the literature. BMC Med. 2014;12(1):192.
Crossref
PubMed
Google Scholar
8.
Horgan D, Nobili F, Teunissen C, et al. Biomarker testing: piercing the fog of Alzheimer's and related dementia denis. Biomed Hub. 2021;5(3):63.
Crossref
Google Scholar
9.
Brisson M, Brodeur C, Létourneau-Guillon L, et al. CCCDTD5: clinical role of neuroimaging and liquid biomarkers in patients with cognitive impairment. Alzheimers Dement (NY). 2020;6(1):e12098.
Crossref
Google Scholar
10.
Expert Panel on Neurological Imaging, Moonis G, Subramaniam RM, Trofimova A, et al. ACR Appropriateness Criteria® dementia. J Am Coll Radiol. 2020;17(5S):S100–S112.
Crossref
PubMed
Google Scholar
11.
Nobili F, Arbizu J, Bouwman F, et al; EANM-EAN Task Force for the Prescription of FDG-PET for Dementing Neurodegenerative Disorders. European Association of Nuclear Medicine and European Academy of Neurology recommendations for the use of brain 18 F-fluorodeoxyglucose positron emission tomography in neurodegenerative cognitive impairment and dementia: delphi consensus. Eur J Neurol. 2018;25(10):1201-1217.
Crossref
PubMed
Google Scholar
12.
Rosa-Neto P, Hsiung GYR, Masellis M; CCDTD4 participants. Fluid biomarkers for diagnosing dementia: rationale and the Canadian consensus on diagnosis and treatment of dementia recommendations for Canadian physicians. Alzheimers Res Ther. 2013;5(suppl 1):S8–S12.
Crossref
PubMed
Google Scholar
13.
Shaw LM, Arias J, Blennow K, et al. Appropriate use criteria for lumbar puncture and cerebrospinal fluid testing in the diagnosis of Alzheimer's disease. Alzheimers Dement. 2018;14(11):1505-1521.
Crossref
PubMed
Google Scholar
14.
Niemantsverdriet E, Valckx S, Bjerke M, Engelborghs S. Alzheimer's disease CSF biomarkers: clinical indications and rational use. Acta Neurol Belg. 2017;117(3):591-602.
Crossref
PubMed
Google Scholar
15.
Laforce R, Buteau JP, Paquet N, Verret L, Houde M, Bouchard RW. The value of PET in mild cognitive impairment, typical and atypical/unclear dementias: a retrospective memory clinic study. Am J Alzheimers Dis Other Demen. 2010;25(4):324-332.
Crossref
PubMed
Google Scholar
16.
Perini G, Rodriguez-Vieitez E, Kadir A, Sala A, Savitcheva I, Nordberg A. Clinical impact of 18F-FDG-PET among memory clinic patients with uncertain diagnosis. Eur J Nucl Med Mol Imaging 2021;48(2):612-622.
Crossref
PubMed
Google Scholar
17.
Jack CR, Hampel HJ. Universities S, Cu M, Petersen RC. A new classification system for AD, independent of cognition A/T/N : an unbiased descriptive classification scheme for Alzheimer disease biomarkers. Neurology. 2016;87(5):1-10.
Crossref
Google Scholar
18.
Jack CR, Bennett DA, Blennow K, et al; Contributors. NIA-AA Research Framework: toward a biological definition of Alzheimer's disease. Alzheimers Dement. 2018;14(4):535-562.
Crossref
PubMed
Google Scholar
19.
McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7(3):263-269.
Crossref
PubMed
Google Scholar
20.
ADmark® Phospho-Tau/Total-Tau/A Beta42, Analysis and Interp C. Accessed November 3, 2022. athenadiagnostics.com/view-full-catalog/a/admark-reg;-phospho-tau-total-tau-ab42-csf-analysi
Google Scholar
21.
Ferreira D, Perestelo-Pérez L, Westman E, Wahlund LO, Sarria A, Serrano-Aguilar P. Meta-review of CSF core biomarkers in Alzheimer's disease: the state-of-the-art after the new revised diagnostic criteria. Front Aging Neurosci. 2014;6(MAR):47-24.
Crossref
PubMed
Google Scholar
22.
Blennow K. Cerebrospinal fluid protein biomarkers for Alzheimer's disease. NeuroRx. 2004;1(2):213-225.
Crossref
PubMed
Google Scholar
23.
Hulstaert F, Blennow K, Ivanoiu A, et al. Improved discrimination of AD patients using beta-amyloid(1-42) and tau levels in CSF. Neurology. 1999;52(8):1555-1562.
Crossref
PubMed
Google Scholar
24.
Morbelli S, Brugnolo A, Bossert I, et al. Visual versus semi-quantitative analysis of 18F-FDG-PET in Amnestic MCI: An European Alzheimer's disease Consortium (EADC) project. J Alzheimers Dis. 2015;44(3):815-826.
Crossref
PubMed
Google Scholar
25.
Nestor PJ, Altomare D, Festari C, et al; EANM-EAN Task Force for the Prescription of FDG-PET for Dementing Neurodegenerative Disorders. Clinical utility of FDG-PET for the differential diagnosis among the main forms of dementia. Eur J Nucl Med Mol Imaging. 2018;45(9):1509-1525.
Crossref
PubMed
Google Scholar
26.
Raichle ME, Snyder AZ. A default mode of brain function: a brief history of an evolving idea. Neuroimage. 2007;37(4):1083-1090; discussion 1097-1099.
Crossref
PubMed
Google Scholar
27.
Buckner RL, Sepulcre J, Talukdar T, et al. Cortical hubs revealed by intrinsic functional connectivity: mapping, assessment of stability, and relation to Alzheimer's disease. J Neurosci. 2009;29(6):1860-1873.
Crossref
PubMed
Google Scholar
28.
Cognat E, Mouton Liger F, Troussière AC, et al; ePLM network. What is the clinical impact of cerebrospinal fluid biomarkers on final diagnosis and management in patients with mild cognitive impairment in clinical practice? Results from a nation-wide prospective survey in France. BMJ Open. 2019;9(5):e026380-e026386.
Crossref
PubMed
Google Scholar
29.
Simonsen AH, Herukka SK, Andreasen N, et al. Recommendations for CSF AD biomarkers in the diagnostic evaluation of dementia. Alzheimers Dement. 2017;13(3):274-284.
Crossref
PubMed
Google Scholar
30.
Leuzy A, Ashton NJ, Mattsson-Carlgren N, et al. 2020 update on the clinical validity of cerebrospinal fluid amyloid, tau, and phospho-tau as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework. Eur J Nucl Med Mol Imaging. 2021;48(7):2121-2139.
Crossref
PubMed
Google Scholar
31.
Deture MA, Dickson DW. The neuropathological diagnosis of Alzheimer's disease. Mol Neurodegener. 2019;14(1):32-18.
Crossref
PubMed
Google Scholar
32.
Hansson O, Mikulskis A, Fagan AM, et al. The impact of preanalytical variables on measuring cerebrospinal fluid biomarkers for Alzheimer's disease diagnosis: A review. Alzheimers Dement. 2018;14(10):1313-1333.
Crossref
PubMed
Google Scholar
33.
Frisoni GB, Boccardi M, Barkhof F, et al. Strategic roadmap for an early diagnosis of Alzheimer's disease based on biomarkers. Lancet Neurol. 2017;16(8):661-676.
Crossref
PubMed
Google Scholar
34.
Caminiti SP, Ballarini T, Sala A, et al; BIOMARKAPD Project. FDG-PET and CSF biomarker accuracy in prediction of conversion to different dementias in a large multicentre MCI cohort. Neuroimage Clin. 2018;18(November 2017):167-177.
Crossref
PubMed
Google Scholar
35.
Massa F, Farotti L, Eusebi P, et al. Reciprocal incremental value of 18F-FDG-PET and cerebrospinal fluid biomarkers in mild cognitive impairment patients suspected for Alzheimer's disease and inconclusive first biomarker. J Alzheimers Dis. 2019;72(4):1193-1207.
Crossref
PubMed
Google Scholar
36.
Choo IH, Ni R, Schöll M, Wall A, Almkvist O, Nordberg A. Combination of 18F-FDG PET and cerebrospinal fluid biomarkers as a better predictor of the progression to Alzheimer's disease in mild cognitive impairment patients. J Alzheimers Dis. 2013;33(4):929-939.
Crossref
PubMed
Google Scholar
37.
Yakushev I, Muller MJ, Buchholz H-G, et al. Stage-dependent agreement between cerebrospinal fluid proteins and FDG-PET findings in Alzheimer's disease. Curr Alzheimer Res. 2012;9(2):241-247.
Crossref
PubMed
Google Scholar
38.
Rubí S, Noguera A, Tarongí S, et al. Concordance between brain 18 F-FDG PET and cerebrospinal fluid biomarkers in diagnosing Alzheimer's disease. Revista espanola de medicina Nucl e imagen Mol. 2018;37(1):3-8.
Crossref
PubMed
Google Scholar
39.
Lesman-Segev OH, La Joie R, Iaccarino L, et al. Diagnostic accuracy of amyloid versus 18F-fluorodeoxyglucose positron emission tomography in autopsy-confirmed dementia. Ann Neurol. 2021;89(2):389-401.
Crossref
PubMed
Google Scholar
40.
Whitwell JL, Graff-Radford J, Singh TD, et al. 18F-FDG PET in posterior cortical atrophy and dementia with lewy bodies. J Nucl Med. 2017;58(4):632-638.
Crossref
PubMed
Google Scholar
41.
Lehmann M, Ghosh PM, Madison C, et al. Diverging patterns of amyloid deposition and hypometabolism in clinical variants of probable Alzheimer's disease. Brain. 2013;136(Pt 3):844-858.
Crossref
PubMed
Google Scholar
42.
Ng S, Villemagne VL, Berlangieri S, et al. Visual assessment versus quantitative assessment of 11C-PIB PET and 18F-FDG PET for detection of Alzheimer's disease. J Nucl Med. 2007;48(4):547-552.
Crossref
PubMed
Google Scholar
43.
Jack CR, Knopman DS, Chételat G, et al. Suspected non-Alzheimer disease pathophysiology-concept and controversy. Nat Rev Neurol. 2016;12(2):117-124.
Crossref
PubMed
Google Scholar
44.
Dani M, Brooks DJ, Edison P. Suspected non Alzheimer's pathology – is it non-Alzheimer’s or non-amyloid?. Ageing Res Rev. 2017;36:20-31.
Crossref
PubMed
Google Scholar
45.
Bateman RJ, Xiong C, Benzinger TLS, et al; Dominantly Inherited Alzheimer Network. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med. 2012;367(9):795-804.
Crossref
PubMed
Google Scholar
46.
Jack CR Jr, Knopman DS, Jagust WJ, et al. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 2013;12(2):207-216.
Crossref
PubMed
Google Scholar
47.
Wirth M, Bejanin A, La Joie R, et al. Regional patterns of gray matter volume, hypometabolism, and beta-amyloid in groups at risk of Alzheimer's disease. Neurobiol Aging. 2018;63:140-151.
Crossref
PubMed
Google Scholar
48.
Landau SM, Lu M, Joshi AD, et al; Alzheimer's Disease Neuroimaging, Initiative. Comparing positron emission tomography imaging and cerebrospinal fluid measurements of β-amyloid. Ann Neurol. 2013;74(6):826-836.
Crossref
PubMed
Google Scholar
49.
Teune LK, Strijkert F, Renken RJ, et al. The Alzheimer's disease-related glucose metabolic brain pattern. Curr Alzheimer Res. 2014;11(8):725-732.
Crossref
PubMed
Google Scholar
50.
Rabinovici GD, Rosen HJ, Alkalay A, et al. Amyloid vs FDG-PET in the differential diagnosis of AD and FTLD. Neurology. 2011;77(23):2034-2042.
Crossref
PubMed
Google Scholar

Information & Authors

Information

Published In

Neurology®
Volume 99 • Number 22 • November 29, 2022
Pages: e2428-e2436
PubMed: 36266044

Copyright

© 2022 American Academy of Neurology.

Publication History

Received: October 14, 2021
Accepted: July 19, 2022
Published online: October 20, 2022
Published in issue: November 29, 2022

Permissions

Request permissions for this article.

Disclosure

The authors report no relevant disclosures. Go to Neurology.org/N for full disclosures.

Study Funding

This work was supported by the Canadian Institutes of Health Research (CIHR) [MOP-11-51-31; RFN 152985, 159815, 162303], Canadian Consortium of Neurodegeneration and Aging (CCNA; MOP-11-51-31 -team 1), Weston Brain Institute, the Alzheimer's Association [NIRG-12-92090, NIRP-12-259245], Brain Canada Foundation (CFI Project 34874; 33397), the Fonds de Recherche du Québec—Santé (FRQS; Chercheur Boursier, 2020-VICO-279314). TAP, P.R-N, and SG are members of the CIHR-CCNA Canadian Consortium of Neurodegeneration in Aging.

Authors

Affiliations & Disclosures

Kely Mónica Quispialaya, MD*
From the Translational Neuroimaging Laboratory (K.M.Q., J.T., M.Z., J.F.-A., F.L., S.G., P.V., P.R.-N.), The McGill University Research Centre for Studies in Aging, Douglas Hospital, McGill University, Montreal, Quebec, Canada; Research Institute of the McGill University Health Centre (K.M.Q., A.A., B.J.-C., B.G.), Montreal, Quebec, Canada; Departments of Medicine (K.M.Q., B.J.-C., B.G.) and Neurology and Neurosurgery (J.T., M.Z., J.F.-A., F.L., J.-P.S., S.G., P.V., P.R.-N.), McGill University, Montreal, Quebec, Canada; Montreal Neurological Institute (J.T., M.Z., J.F.-A., F.L., G.M., J.-P.S., P.R.-N.), Montreal, Quebec, Canada; Department of Radiochemistry (G.M.), McGill University, Montreal, Quebec, Canada; Department of Psychiatry (T.P.), Pittsburgh University, PA; and Department of Psychiatry (S.G., P.R.-N.), McGill University, Montreal, Quebec, Canada.
Disclosure
Scientific Advisory Boards:
1.
None
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
None
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
None
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Joseph Therriault, BSc*
From the Translational Neuroimaging Laboratory (K.M.Q., J.T., M.Z., J.F.-A., F.L., S.G., P.V., P.R.-N.), The McGill University Research Centre for Studies in Aging, Douglas Hospital, McGill University, Montreal, Quebec, Canada; Research Institute of the McGill University Health Centre (K.M.Q., A.A., B.J.-C., B.G.), Montreal, Quebec, Canada; Departments of Medicine (K.M.Q., B.J.-C., B.G.) and Neurology and Neurosurgery (J.T., M.Z., J.F.-A., F.L., J.-P.S., S.G., P.V., P.R.-N.), McGill University, Montreal, Quebec, Canada; Montreal Neurological Institute (J.T., M.Z., J.F.-A., F.L., G.M., J.-P.S., P.R.-N.), Montreal, Quebec, Canada; Department of Radiochemistry (G.M.), McGill University, Montreal, Quebec, Canada; Department of Psychiatry (T.P.), Pittsburgh University, PA; and Department of Psychiatry (S.G., P.R.-N.), McGill University, Montreal, Quebec, Canada.
Disclosure
Scientific Advisory Boards:
1.
None
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
None
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
1) Canadian Institutes of Health Research
Research Support, Academic Entities:
1.
1) McGill University Faculty of Medicine<br>2) McGill University Healthy Brains Healthy Lives <br>Initiative
Research Support, Foundations and Societies:
1.
None
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Antonio Aliaga, MSc
From the Translational Neuroimaging Laboratory (K.M.Q., J.T., M.Z., J.F.-A., F.L., S.G., P.V., P.R.-N.), The McGill University Research Centre for Studies in Aging, Douglas Hospital, McGill University, Montreal, Quebec, Canada; Research Institute of the McGill University Health Centre (K.M.Q., A.A., B.J.-C., B.G.), Montreal, Quebec, Canada; Departments of Medicine (K.M.Q., B.J.-C., B.G.) and Neurology and Neurosurgery (J.T., M.Z., J.F.-A., F.L., J.-P.S., S.G., P.V., P.R.-N.), McGill University, Montreal, Quebec, Canada; Montreal Neurological Institute (J.T., M.Z., J.F.-A., F.L., G.M., J.-P.S., P.R.-N.), Montreal, Quebec, Canada; Department of Radiochemistry (G.M.), McGill University, Montreal, Quebec, Canada; Department of Psychiatry (T.P.), Pittsburgh University, PA; and Department of Psychiatry (S.G., P.R.-N.), McGill University, Montreal, Quebec, Canada.
Disclosure
Scientific Advisory Boards:
1.
None
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
None
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
None
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Maria Zimmermann, BSc
From the Translational Neuroimaging Laboratory (K.M.Q., J.T., M.Z., J.F.-A., F.L., S.G., P.V., P.R.-N.), The McGill University Research Centre for Studies in Aging, Douglas Hospital, McGill University, Montreal, Quebec, Canada; Research Institute of the McGill University Health Centre (K.M.Q., A.A., B.J.-C., B.G.), Montreal, Quebec, Canada; Departments of Medicine (K.M.Q., B.J.-C., B.G.) and Neurology and Neurosurgery (J.T., M.Z., J.F.-A., F.L., J.-P.S., S.G., P.V., P.R.-N.), McGill University, Montreal, Quebec, Canada; Montreal Neurological Institute (J.T., M.Z., J.F.-A., F.L., G.M., J.-P.S., P.R.-N.), Montreal, Quebec, Canada; Department of Radiochemistry (G.M.), McGill University, Montreal, Quebec, Canada; Department of Psychiatry (T.P.), Pittsburgh University, PA; and Department of Psychiatry (S.G., P.R.-N.), McGill University, Montreal, Quebec, Canada.
Disclosure
Scientific Advisory Boards:
1.
None
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
None
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
(1) Savoy Foundation
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Jaime Fernandez-Arias, MSc
From the Translational Neuroimaging Laboratory (K.M.Q., J.T., M.Z., J.F.-A., F.L., S.G., P.V., P.R.-N.), The McGill University Research Centre for Studies in Aging, Douglas Hospital, McGill University, Montreal, Quebec, Canada; Research Institute of the McGill University Health Centre (K.M.Q., A.A., B.J.-C., B.G.), Montreal, Quebec, Canada; Departments of Medicine (K.M.Q., B.J.-C., B.G.) and Neurology and Neurosurgery (J.T., M.Z., J.F.-A., F.L., J.-P.S., S.G., P.V., P.R.-N.), McGill University, Montreal, Quebec, Canada; Montreal Neurological Institute (J.T., M.Z., J.F.-A., F.L., G.M., J.-P.S., P.R.-N.), Montreal, Quebec, Canada; Department of Radiochemistry (G.M.), McGill University, Montreal, Quebec, Canada; Department of Psychiatry (T.P.), Pittsburgh University, PA; and Department of Psychiatry (S.G., P.R.-N.), McGill University, Montreal, Quebec, Canada.
Disclosure
Scientific Advisory Boards:
1.
None
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
None
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
None
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Firoza Lussier, MSc
From the Translational Neuroimaging Laboratory (K.M.Q., J.T., M.Z., J.F.-A., F.L., S.G., P.V., P.R.-N.), The McGill University Research Centre for Studies in Aging, Douglas Hospital, McGill University, Montreal, Quebec, Canada; Research Institute of the McGill University Health Centre (K.M.Q., A.A., B.J.-C., B.G.), Montreal, Quebec, Canada; Departments of Medicine (K.M.Q., B.J.-C., B.G.) and Neurology and Neurosurgery (J.T., M.Z., J.F.-A., F.L., J.-P.S., S.G., P.V., P.R.-N.), McGill University, Montreal, Quebec, Canada; Montreal Neurological Institute (J.T., M.Z., J.F.-A., F.L., G.M., J.-P.S., P.R.-N.), Montreal, Quebec, Canada; Department of Radiochemistry (G.M.), McGill University, Montreal, Quebec, Canada; Department of Psychiatry (T.P.), Pittsburgh University, PA; and Department of Psychiatry (S.G., P.R.-N.), McGill University, Montreal, Quebec, Canada.
Disclosure
Scientific Advisory Boards:
1.
None
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
None
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
Fonds de recherche du Qu&#x00E9;bec - Sant&#x00E9;
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Gassan Massarweh, PhD
From the Translational Neuroimaging Laboratory (K.M.Q., J.T., M.Z., J.F.-A., F.L., S.G., P.V., P.R.-N.), The McGill University Research Centre for Studies in Aging, Douglas Hospital, McGill University, Montreal, Quebec, Canada; Research Institute of the McGill University Health Centre (K.M.Q., A.A., B.J.-C., B.G.), Montreal, Quebec, Canada; Departments of Medicine (K.M.Q., B.J.-C., B.G.) and Neurology and Neurosurgery (J.T., M.Z., J.F.-A., F.L., J.-P.S., S.G., P.V., P.R.-N.), McGill University, Montreal, Quebec, Canada; Montreal Neurological Institute (J.T., M.Z., J.F.-A., F.L., G.M., J.-P.S., P.R.-N.), Montreal, Quebec, Canada; Department of Radiochemistry (G.M.), McGill University, Montreal, Quebec, Canada; Department of Psychiatry (T.P.), Pittsburgh University, PA; and Department of Psychiatry (S.G., P.R.-N.), McGill University, Montreal, Quebec, Canada.
Disclosure
Scientific Advisory Boards:
1.
None
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
None
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
None
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Tharick Pascoal, MD, PhD
From the Translational Neuroimaging Laboratory (K.M.Q., J.T., M.Z., J.F.-A., F.L., S.G., P.V., P.R.-N.), The McGill University Research Centre for Studies in Aging, Douglas Hospital, McGill University, Montreal, Quebec, Canada; Research Institute of the McGill University Health Centre (K.M.Q., A.A., B.J.-C., B.G.), Montreal, Quebec, Canada; Departments of Medicine (K.M.Q., B.J.-C., B.G.) and Neurology and Neurosurgery (J.T., M.Z., J.F.-A., F.L., J.-P.S., S.G., P.V., P.R.-N.), McGill University, Montreal, Quebec, Canada; Montreal Neurological Institute (J.T., M.Z., J.F.-A., F.L., G.M., J.-P.S., P.R.-N.), Montreal, Quebec, Canada; Department of Radiochemistry (G.M.), McGill University, Montreal, Quebec, Canada; Department of Psychiatry (T.P.), Pittsburgh University, PA; and Department of Psychiatry (S.G., P.R.-N.), McGill University, Montreal, Quebec, Canada.
Disclosure
Scientific Advisory Boards:
1.
None
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
None
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
None
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Jean-Paul Soucy, MD, MSc
From the Translational Neuroimaging Laboratory (K.M.Q., J.T., M.Z., J.F.-A., F.L., S.G., P.V., P.R.-N.), The McGill University Research Centre for Studies in Aging, Douglas Hospital, McGill University, Montreal, Quebec, Canada; Research Institute of the McGill University Health Centre (K.M.Q., A.A., B.J.-C., B.G.), Montreal, Quebec, Canada; Departments of Medicine (K.M.Q., B.J.-C., B.G.) and Neurology and Neurosurgery (J.T., M.Z., J.F.-A., F.L., J.-P.S., S.G., P.V., P.R.-N.), McGill University, Montreal, Quebec, Canada; Montreal Neurological Institute (J.T., M.Z., J.F.-A., F.L., G.M., J.-P.S., P.R.-N.), Montreal, Quebec, Canada; Department of Radiochemistry (G.M.), McGill University, Montreal, Quebec, Canada; Department of Psychiatry (T.P.), Pittsburgh University, PA; and Department of Psychiatry (S.G., P.R.-N.), McGill University, Montreal, Quebec, Canada.
Disclosure
Scientific Advisory Boards:
1.
None
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
(1) I received a payment from GE Canada for a series of 2 <br>courses on the clinical use of 123I-ioflupane, given to <br>Nuclear Medicine specialists in Alberta<br>(2) I have been paid by Biogen for giving courses to <br>physicians
Editorial Boards:
1.
Member, Editorial Board, Brain Connectivity, 2022-
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
1) Non-profit entity: Consultant to INESSS, the Quebec <br>Government National Institute for Excellence in Health and <br>Social Services, on the clinical use of 123I-ioflupane for <br>SPECT imaging of the dopamine transporter<br>2) Participated in a group on Alzheimer's therapy organized <br>by Biogen Canada
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
I practice Nuclear Medicine at both the Montreal<br>University Medical Centre and Montreal Neurological<br>Hospital, and I report both SPECT rCBF studies and PET FDG<br>brain studies as a practitioner. New PET imaging agents might <br>be approved in Canada for clinical use in the future.
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
24.Beta-cell imaging with 18F-labeled<br>glibenclamide-glucose conjugates by positron emission<br>tomography. CIHR 97970; SCHIRRMACHER, R, SOUCY, JP;<br>$79,462/ann&#x00E9;e x 3 ans (2010)<br>25.Sleep and mild cognitive impairment. CIHR MOP-<br>102631.<br>MONTPLAISIR J, GAGNON JF, GOSSELIN N, MONCHY O, SOUCY JP.<br>$169,465/ann&#x00E9;e X 5 ans (2010)<br>26.Anatomobehavioral validation of the<br>[18F]fluoroethoxybenzovesamicol, as a PET radiotracer for<br>the diagnosis of Alzheimer&#x0092;s disease. CIHR. Co-PI: B&#x00C9;DARD<br>MA, SOUCY JP, ROSA P. Collaborators : DESCARRIES L,<br>MESHAWAR N. $50 000.00 X 1 an (2010)<br>27.Development of an automated blood counter for<br>quantitative molecular imaging applications. Despr&#x00E9;s,<br>Philippe (IP). CO-APPLICANT(S): Soucy, Jean-Paul; Rosa<br>Neto, Pedro; Hamel, Louis-Andr&#x00E9;. Projets de recherche<br>concert&#x00E9;e sur la sant&#x00E9; (PRCS), programme conjoint CRSNG <br>et<br>IRSC. Projet # 1004158. 2010: $73000, 2011: $110300, <br>2012:<br>$61800<br>28.In vivo quantification of glutamatergic <br>abnormalities<br>in patients with Alzheimer's disease. Rosa-Neto, Pedro<br>(IP); Co-applicants: Gauthier, Serge; Soucy, Jean-Paul.<br>IRSC, demande # 245908, comit&#x00E9; BCA. $196,180/ann&#x00E9;e X 4<br>ans (2011-2014)<br>29.The neuro-circuitry of terror: High resolution <br>SPECT<br>imaging of REM sleep in PTSD and Nightmare Disorder. IPs:<br>Nielsen, Torre; Soucy, Jean-Paul. Co-applicant:<br>Montplaisir, Jacques. CIHR MOP-115125. $135 550/ann&#x00E9;e X 5<br>ans (2011-2015)<br>30.Anomia in Alzheimer&#x0092;s disease : Untangling <br>semantic<br>components and delivering therapy with rTMS. Chertkow<br>Howard, Soucy Jean-Paul, Thiel Alexander. CIHR 259005.<br>$153 303.00/year, 2012-2015<br>31.Obstructive sleep apnea and mild cognitive <br>impairment.<br>N Gosselin, J. Y. Montplaisir, L. De Beaumont, J. <br>Gagnon,<br>S. Gauthier, J. P. Soucy. CIHR 272199. $157,816/ann&#x00E9;e,<br>2012-2016
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
None
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Serge Gauthier, MD
From the Translational Neuroimaging Laboratory (K.M.Q., J.T., M.Z., J.F.-A., F.L., S.G., P.V., P.R.-N.), The McGill University Research Centre for Studies in Aging, Douglas Hospital, McGill University, Montreal, Quebec, Canada; Research Institute of the McGill University Health Centre (K.M.Q., A.A., B.J.-C., B.G.), Montreal, Quebec, Canada; Departments of Medicine (K.M.Q., B.J.-C., B.G.) and Neurology and Neurosurgery (J.T., M.Z., J.F.-A., F.L., J.-P.S., S.G., P.V., P.R.-N.), McGill University, Montreal, Quebec, Canada; Montreal Neurological Institute (J.T., M.Z., J.F.-A., F.L., G.M., J.-P.S., P.R.-N.), Montreal, Quebec, Canada; Department of Radiochemistry (G.M.), McGill University, Montreal, Quebec, Canada; Department of Psychiatry (T.P.), Pittsburgh University, PA; and Department of Psychiatry (S.G., P.R.-N.), McGill University, Montreal, Quebec, Canada.
Disclosure
Scientific Advisory Boards:
1.
DSMB<br>(1) Commercia entity: Eisai<br>(2) Non-commercial entities: ATRI, ADCS, Banner-Health<br>Scientific advisor, commercial entities: Boeringer-<br>Ingelheim, TauRx, Lilly
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
None
Editorial Boards:
1.
JPAD, Associate Editor. No financial compensation.<br>Neurotorium, member of editorial board. Financial <br>compensation 1,000 Euros/yea
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
For-profit entity: Cerveau, AmyriAD, Roche Canada, Biogen <br>Canada
Speakers' Bureaus:
1.
Biogen Canada
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
None
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Bertrand Jean-Claude, PhD
From the Translational Neuroimaging Laboratory (K.M.Q., J.T., M.Z., J.F.-A., F.L., S.G., P.V., P.R.-N.), The McGill University Research Centre for Studies in Aging, Douglas Hospital, McGill University, Montreal, Quebec, Canada; Research Institute of the McGill University Health Centre (K.M.Q., A.A., B.J.-C., B.G.), Montreal, Quebec, Canada; Departments of Medicine (K.M.Q., B.J.-C., B.G.) and Neurology and Neurosurgery (J.T., M.Z., J.F.-A., F.L., J.-P.S., S.G., P.V., P.R.-N.), McGill University, Montreal, Quebec, Canada; Montreal Neurological Institute (J.T., M.Z., J.F.-A., F.L., G.M., J.-P.S., P.R.-N.), Montreal, Quebec, Canada; Department of Radiochemistry (G.M.), McGill University, Montreal, Quebec, Canada; Department of Psychiatry (T.P.), Pittsburgh University, PA; and Department of Psychiatry (S.G., P.R.-N.), McGill University, Montreal, Quebec, Canada.
Disclosure
Scientific Advisory Boards:
1.
None
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
None
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
None
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Brian Gilfix, MD, PhD
From the Translational Neuroimaging Laboratory (K.M.Q., J.T., M.Z., J.F.-A., F.L., S.G., P.V., P.R.-N.), The McGill University Research Centre for Studies in Aging, Douglas Hospital, McGill University, Montreal, Quebec, Canada; Research Institute of the McGill University Health Centre (K.M.Q., A.A., B.J.-C., B.G.), Montreal, Quebec, Canada; Departments of Medicine (K.M.Q., B.J.-C., B.G.) and Neurology and Neurosurgery (J.T., M.Z., J.F.-A., F.L., J.-P.S., S.G., P.V., P.R.-N.), McGill University, Montreal, Quebec, Canada; Montreal Neurological Institute (J.T., M.Z., J.F.-A., F.L., G.M., J.-P.S., P.R.-N.), Montreal, Quebec, Canada; Department of Radiochemistry (G.M.), McGill University, Montreal, Quebec, Canada; Department of Psychiatry (T.P.), Pittsburgh University, PA; and Department of Psychiatry (S.G., P.R.-N.), McGill University, Montreal, Quebec, Canada.
Disclosure
Scientific Advisory Boards:
1.
None
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
None
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
None
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Paolo Vitali, MD, PhD https://orcid.org/0000-0001-8953-1542
From the Translational Neuroimaging Laboratory (K.M.Q., J.T., M.Z., J.F.-A., F.L., S.G., P.V., P.R.-N.), The McGill University Research Centre for Studies in Aging, Douglas Hospital, McGill University, Montreal, Quebec, Canada; Research Institute of the McGill University Health Centre (K.M.Q., A.A., B.J.-C., B.G.), Montreal, Quebec, Canada; Departments of Medicine (K.M.Q., B.J.-C., B.G.) and Neurology and Neurosurgery (J.T., M.Z., J.F.-A., F.L., J.-P.S., S.G., P.V., P.R.-N.), McGill University, Montreal, Quebec, Canada; Montreal Neurological Institute (J.T., M.Z., J.F.-A., F.L., G.M., J.-P.S., P.R.-N.), Montreal, Quebec, Canada; Department of Radiochemistry (G.M.), McGill University, Montreal, Quebec, Canada; Department of Psychiatry (T.P.), Pittsburgh University, PA; and Department of Psychiatry (S.G., P.R.-N.), McGill University, Montreal, Quebec, Canada.
Disclosure
Scientific Advisory Boards:
1.
None
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
None
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
None
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Pedro Rosa-Neto, MD, PhD https://orcid.org/0000-0001-9116-1376
From the Translational Neuroimaging Laboratory (K.M.Q., J.T., M.Z., J.F.-A., F.L., S.G., P.V., P.R.-N.), The McGill University Research Centre for Studies in Aging, Douglas Hospital, McGill University, Montreal, Quebec, Canada; Research Institute of the McGill University Health Centre (K.M.Q., A.A., B.J.-C., B.G.), Montreal, Quebec, Canada; Departments of Medicine (K.M.Q., B.J.-C., B.G.) and Neurology and Neurosurgery (J.T., M.Z., J.F.-A., F.L., J.-P.S., S.G., P.V., P.R.-N.), McGill University, Montreal, Quebec, Canada; Montreal Neurological Institute (J.T., M.Z., J.F.-A., F.L., G.M., J.-P.S., P.R.-N.), Montreal, Quebec, Canada; Department of Radiochemistry (G.M.), McGill University, Montreal, Quebec, Canada; Department of Psychiatry (T.P.), Pittsburgh University, PA; and Department of Psychiatry (S.G., P.R.-N.), McGill University, Montreal, Quebec, Canada.
Disclosure
Scientific Advisory Boards:
1.
(1) Enigma radiopharmaceutical<br>(2) Kalgene
Gifts:
1.
Novo Nordisk - Educational symposium at ADPD2022, <br>Barcelona.
Funding for Travel or Speaker Honoraria:
1.
None
Editorial Boards:
1.
associate editor: Frontier in Aging Neurosciences
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
(1) Enigma pharmaceuticals<br>(2) Eli-Lilly
Research Support, Government Entities:
1.
(1) FRSQ, 35271, principal applicant, 2014-2018<br>(2) CIHR, 363444, co-applicant, 2016-2019<br>(3) CIHR, 366009, co-applicant, 2016-2020<br>(4) CIHR, 201312CNA-322265-CNA-CFAF-32054, co-<br>investigator, 2014-2019
Research Support, Academic Entities:
1.
(1) Merck, Sharpe & Dohme Corporation/McGill Faculty of <br>Medicine Grant for Translational Research
Research Support, Foundations and Societies:
1.
(1) Weston Brain Institute<br>(2) Alzheimer's Association<br>(3) Brain Canada CQDM
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author

Notes

Correspondence Dr. Rosa-Neto [email protected]
*
These authors contributed equally as first authors.
Go to Neurology.org/N for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.
Submitted and externally peer reviewed. The handling editor was Rawan Tarawneh, MD.

Metrics & Citations

Metrics

Citation information is sourced from Crossref Cited-by service.

Citations

Download Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.

Cited By
    • Kely Monica Quispialaya,
    • Joseph Therriault,
    • Antonio Aliaga,
    • Andrea L. Benedet,
    • Nicholas J. Ashton,
    • Thomas Karikari,
    • Arthur Cassa Macedo,
    • Nesrine Rahmouni,
    • Cécile Tissot,
    • Jaime Fernandez Arias,
    • Yi-Ting Tina Wang,
    • Lydia Trudel,
    • Seyyed Ali Hosseini,
    • Takashi Matsudaira,
    • Tevy Chan,
    • Tharick Pascoal,
    • Brian Gilfix,
    • Paolo Vitali,
    • Eduardo R. Zimmer,
    • Karine Provost,
    • Jean-Paul Soucy,
    • Serge Gauthier,
    • Henrik Zetterberg,
    • Bertrand J. Jean-Claude,
    • Kaj Blennow,
    • Pedro Rosa-Neto,
    Comparison of Plasma p-tau217 and [18F]FDG-PET for Identifying Alzheimer Disease in People With Early-Onset or Atypical Dementia, Neurology, 104, 2, (2025)./doi/10.1212/WNL.0000000000210211
    Abstract
    • Hyeon soo Kim,
    • Haram Jung,
    • Yong Ho Park,
    • Su-Hak Heo,
    • Sujin Kim,
    • Minho Moon,
    Skin-brain axis in Alzheimer's disease - Pathologic, diagnostic, and therapeutic implications: A Hypothetical Review, Aging and disease, 16, 2, (901), (2025).https://doi.org/10.14336/AD.2024.0406
    Crossref
    • Théodore Decaix,
    • François Mouton-Liger,
    • Julien Dumurgier,
    • Emmanuel Cognat,
    • Agathe Vrillon,
    • Jacques Hugon,
    • Claire Hourregue,
    • Elodie Bouaziz-Amar,
    • David Wallon,
    • Muriel Quillard Muraine,
    • Anne-Cécile Troussière,
    • Eloi Magnin,
    • Emmanuelle Duron,
    • Nathalie Philippi,
    • Frédéric Blanc,
    • Audrey Gabelle,
    • Bernard Croisile,
    • Alain Jager,
    • Florence Pasquier,
    • Susanna Schraen,
    • Vincent de la Sayette,
    • Émilie Beaufils,
    • Carole Miguet-Alfonsi,
    • Claire Paquet,
    • Matthieu Lilamand,
    Usefulness of Cerebrospinal Fluid Alzheimer's disease biomarkers in older patients: Evidence from a national multicenter prospective study, The Journal of Prevention of Alzheimer's Disease, 12, 1, (100009), (2025).https://doi.org/10.1016/j.tjpad.2024.100009
    Crossref
    • Bradford C. Dickerson,
    • Alireza Atri,
    • Carolyn Clevenger,
    • Jason Karlawish,
    • David Knopman,
    • Pei‐Jung Lin,
    • Mary Norman,
    • Chiadi Onyike,
    • Mary Sano,
    • Susan Scanland,
    • Maria Carrillo,
    The Alzheimer's Association clinical practice guideline for the Diagnostic Evaluation, Testing, Counseling, and Disclosure of Suspected Alzheimer's Disease and Related Disorders (DETeCD‐ADRD): Executive summary of recommendations for specialty care, Alzheimer's & Dementia, 21, 1, (2024).https://doi.org/10.1002/alz.14337
    Crossref
    • Kely Monica Quispialaya,
    • Joseph Therriault,
    • Antonio Aliaga,
    • Cécile Tissot,
    • Stijn Servaes,
    • Nesrine Rahmouni,
    • Thomas K. Karikari,
    • Andrea L. Benedet,
    • Nicholas J. Ashton,
    • Arthur C. Macedo,
    • Firoza Z. Lussier,
    • Jenna Stevenson,
    • Yi‐Ting Wang,
    • Jaime Fernandez Arias,
    • Ali Hosseini,
    • Takashi Matsudaira,
    • Bertrand Jean‐Claude,
    • Brian M. Gilfix,
    • Eduardo R. Zimmer,
    • Jean‐Paul Soucy,
    • Tharick A. Pascoal,
    • Serge Gauthier,
    • Henrik Zetterberg,
    • Kaj Blennow,
    • Pedro Rosa‐Neto,
    Plasma phosphorylated tau181 outperforms [ 18 F ] fluorodeoxyglucose positron emission tomography in the identification of early Alzheimer disease , European Journal of Neurology, 31, 12, (2024).https://doi.org/10.1111/ene.16255
    Crossref
    • Joseph Therriault,
    • Marcel S. Woo,
    • Gemma Salvadó,
    • Johan Gobom,
    • Thomas K. Karikari,
    • Shorena Janelidze,
    • Stijn Servaes,
    • Nesrine Rahmouni,
    • Cécile Tissot,
    • Nicholas J. Ashton,
    • Andréa Lessa Benedet,
    • Laia Montoliu-Gaya,
    • Arthur C. Macedo,
    • Firoza Z. Lussier,
    • Jenna Stevenson,
    • Paolo Vitali,
    • Manuel A. Friese,
    • Gassan Massarweh,
    • Jean-Paul Soucy,
    • Tharick A. Pascoal,
    • Erik Stomrud,
    • Sebastian Palmqvist,
    • Niklas Mattsson-Carlgren,
    • Serge Gauthier,
    • Henrik Zetterberg,
    • Oskar Hansson,
    • Kaj Blennow,
    • Pedro Rosa-Neto,
    Comparison of immunoassay- with mass spectrometry-derived p-tau quantification for the detection of Alzheimer’s disease pathology, Molecular Neurodegeneration, 19, 1, (2024).https://doi.org/10.1186/s13024-023-00689-2
    Crossref
    • Qiang Huang,
    • Jun Ying,
    • Wen Yu,
    • Yao Dong,
    • Hao Xiong,
    • Yiping Zhang,
    • Jie Liu,
    • Xifeng Wang,
    • Fuzhou Hua,
    P2X7 Receptor: an Emerging Target in Alzheimer’s Disease, Molecular Neurobiology, 61, 5, (2866-2880), (2023).https://doi.org/10.1007/s12035-023-03699-9
    Crossref
    • Danielle Cozachenco,
    • Eduardo R. Zimmer,
    • Mychael V. Lourenco,
    Emerging concepts towards a translational framework in Alzheimer’s disease, Neuroscience & Biobehavioral Reviews, 152, (105246), (2023).https://doi.org/10.1016/j.neubiorev.2023.105246
    Crossref
    • Daniel J. Barber,
    • Colin L. Masters,
    A Tale of Two Platforms, Neurology, 99, 22, (973-974), (2022)./doi/10.1212/WNL.0000000000201532
    Abstract

View Options

Login options

Check if you have access through your login credentials or your institution to get full access on this article.

Personal login Institutional Login
Purchase Options

The neurology.org payment platform is currently offline. Our technical team is working as quickly as possible to restore service.

If you need immediate support or to place an order, please call or email customer service:

  • 1-800-638-3030 for U.S. customers - 8:30 - 7 pm ET (M-F)
  • 1-301-223-2300 for customers outside the U.S. - 8:30 - 7 pm ET (M-F)
  • [email protected]

We appreciate your patience during this time and apologize for any inconvenience.

View options

PDF and All Supplements

Download PDF and Supplementary Material

Short Form

Short Form

Full Text

View Full Text

Full Text HTML

View Full Text HTML

Figures

Tables

Media

Share

Share

Share article link

Share

View full text|Download PDF